NasdaqCM - Nasdaq Real Time Price • USD
DURECT Corporation (DRRX)
As of 2:30 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 1 |
| Avg. Estimate | -0.22 | -0.18 | -1.08 | -1.23 |
| Low Estimate | -0.24 | -0.23 | -1.45 | -1.23 |
| High Estimate | -0.2 | -0.14 | -0.69 | -1.23 |
| Year Ago EPS | -0.5 | -0.46 | -1.2 | -1.08 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 1 |
| Avg. Estimate | 2.72M | 2.82M | 10.65M | 18.04M |
| Low Estimate | 2M | 2M | 8M | 18.04M |
| High Estimate | 3.45M | 3.65M | 15.21M | 18.04M |
| Year Ago Sales | 2.05M | 2.08M | 8.55M | 10.65M |
| Sales Growth (year/est) | 32.40% | 35.50% | 24.60% | 69.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.53 | -0.51 | -0.42 | -0.33 |
| EPS Actual | -0.5 | -0.46 | -0.14 | -0.1 |
| Difference | 0.03 | 0.05 | 0.28 | 0.23 |
| Surprise % | 5.70% | 9.80% | 66.70% | 69.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.22 | -0.18 | -1.08 | -1.23 |
| 7 Days Ago | -0.22 | -0.18 | -1.08 | -1.23 |
| 30 Days Ago | -0.28 | -0.3 | -1.05 | -1.02 |
| 60 Days Ago | -0.28 | -0.3 | -1.05 | -0.81 |
| 90 Days Ago | -0.28 | -0.3 | -1.05 | -0.81 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | DRRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 56.00% | -- | -- | 1.50% |
| Next Qtr. | 60.90% | -- | -- | 12.10% |
| Current Year | 10.00% | -- | -- | 4.40% |
| Next Year | -13.90% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 15.00% | -- | -- | 10.97% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Oppenheimer: Outperform to Outperform | 4/1/2024 |
| Reiterates | HC Wainwright & Co.: Neutral | 3/28/2024 |
| Downgrade | JonesTrading: Buy to Hold | 11/9/2023 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 11/8/2023 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 8/10/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/10/2023 |
Related Tickers
DCPH Deciphera Pharmaceuticals, Inc.
14.63
+3.17%
AGRX Agile Therapeutics, Inc.
0.4000
0.00%
CPHI China Pharma Holdings, Inc.
0.3131
-3.96%
TXMD TherapeuticsMD, Inc.
1.8700
0.00%
ENDPQ Endo International plc
0.0006
0.00%
ITCI Intra-Cellular Therapies, Inc.
72.53
+0.55%
AYTU Aytu BioPharma, Inc.
2.9000
+4.32%
SBFM Sunshine Biopharma, Inc.
1.1550
+43.05%
ESPR Esperion Therapeutics, Inc.
1.9000
-4.52%
BFRI Biofrontera Inc.
1.6601
-2.92%